Business Wire

nShift: Belgian Companies Must Act Fast to Meet Minimum Delivery Options Requirements

6.9.2024 12:15:00 EEST | Business Wire | Press release

Share

Belgium’s online retailers have just 16 days to comply with a new legal requirement to provide their customers with greater delivery choice. New legislation demands that from 21 September, webshops and ecommerce retailers in Belgium must provide at least two methods for the delivery of products to consumers. Retailers will be free to choose the delivery method but (at least) one of the options is encouraged to be eco-friendly.

It’s why nShift, the global leader in experience and delivery management (DMXM) is introducing a new and limited time offer designed to help retailers comply with the new law and offer a better customer experience. New customers in Belgium will receive 25% off a subscription to any of nShift’s solutions for six months.

Sean-Sherwin Smith, Product Director, Post Purchase at nShift said, “The new law marks a major shift in how online retailers will operate across Belgium. The new rule emphasizes sustainability and customer convenience. It marks a significant change in the regulatory landscape and means multi-carrier capability must be central to how retailers operate in the future.

"Sustainability is a core part of nShift’s offer. Our 1000+ carrier library features numerous sustainable last-mile solutions. Our Checkout functionality makes it easier to quickly badge and label more sustainable delivery options so shoppers can quickly find what they are looking for.”

Multi-carrier capability

Retailers will be able to respond to these changes more easily and efficiently if they work with a delivery management partner that offers multi-carrier capabilities. Beyond meeting the new legal requirement, working with a variety of carriers means retailers can offer real choice to shoppers, gain the agility to adapt to shifting consumer demand, and grow their business. Multi-carrier deliveries enable retailers to:

  • Offer a range of delivery options - shoppers expect to find the shipping solution they seek
  • Boost delivery capacity - making it easier to respond to increased demand
  • Improve delivery quality and efficiency – by gaining real data about the performance of each carrier
  • Grow beyond borders - shipping internationally requires relationships with carrier companies that serve the relevant territories
  • Build the brand and remarket to customers – by taking control of customer communications

Multi-carrier capability is at the heart of nShift’s DMXM suite of solutions. It provides enterprise-grade delivery management with a library of 1000+ ready-made carrier connections. nShift can connect retailers and consumers to over one million PUDO (pick up / drop off) locations. Retailers can automate the carrier-booking and label-printing process. This helps retailers send out more parcels, work with more carriers, and tightly control the delivery experience.

Sherwin-Smith concluded, “Businesses affected by the new law need to act fast but it’s also important they make the necessary adjustments in a scalable and sensible way. They must work with a partner that offers choice and convenience, particularly when it comes to eco-friendly carriers and emissions tracking capabilities.”

For more information on the offer or to find out how nShift could help your business with its multi-carrier offering, please visit our website, www.nshift.com.

About nShift

nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

Notes to editors

Under Article VI.45/2 of the Code of Economic Law, webshops will be required to offer at least two delivery methods, including one that is eco-friendly.

This offer is not available to existing customers and cannot be combined with any other discount or promotion. The offer is valid from 00:01 05 September 2024 until midnight on 31 December 2024.

Full subscription agreement will outline contractual terms, Customer will be granted optional termination 90 days from “Start Date”. A minimum of 14 days’ notice of termination must be given. This email does not represent contractual obligation. Promotion excludes existing “Track” service customers; customers with an existing signed “Track” subscription agreement. nShift AB standard terms and conditions apply. Promotional offer will run until 30th November 2023. nShift reserves the right to close promotional offer.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906823045/en/

Contacts

James Ellerington:
James.Ellerington@fourteenforty.uk / (+44) 07725 534941

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye